CD2 and neoplasm: Our finding that TruCs and STARs can more efficiently exploit CD2 to achieve higher antigen sensitivities is consistent with the finding that a STAR outperformed an eTruC and that both outperformed CARs in an in vivo xenograft tumor model (20).